Advances in mesenchymal stem cell biology

Current Opinion in Orthopaedics

Volumn 15, Issue 5, 2004, Pages 341-346

  Dennis, James E ^a   Caplan, Arnold I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell surface markers; Mesenchymal stem cells; Tissue repair

Indexed keywords

CELL SURFACE MARKER;

CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CULTURE TECHNIQUE; HUMAN; MESENCHYME CELL; MESENCHYME STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; SUBSTITUTION THERAPY; TISSUE REGENERATION; TISSUE REPAIR; TREATMENT INDICATION;

EID: 4544293966     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bco.0000134430.30813.f7     Document Type: Review

References (38)

1. Caplan AI, Dennis JE: Mesenchymal stem cell: Progenitors, progeny, and pathways. Bone Min Metab 1996, 14:193-201.
2. Levy YS, Merims D, Panet H, et al.: Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. J Mol Neurosci 2003, 21:121-132.
3. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
4. Shi S, Gronthos S: Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res 2003, 18:696-704. This article illuminates the similarities and differences between MSCs and dental pulp cells (DPSCs) by delineating how both are distinct from endothelial cells, share a smooth muscle cell marker, but vary in the expression of pericyte-associated antigen.
5. Pittenger M, Mackay A, Beck S, et al.: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
6. Dennis JE, Caplan AI: Analysis of the developmental potential of conditionally immortal marrow-derived mesenchymal progenitor cells isolated from the H-2Kb-tsA58 transgenic mouse. Connect Tissue Res 1996, 35:93-99.
7. Dennis JE, Merriam A, Awadallah A, et al.: A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res 1999, 14:700-709.
8. Tallheden T, Dennis JE, Lennon DP, et al.: Phenotypic plasticity of human articular chondrocytes. J Bone Joint Surg 2003, 85-A (suppl 2):93-100.
9. Haynesworth SE, Baber MA, Caplan AI: Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592.
10. Kudo M, Wang Y, Wani MA, et al.: Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. J Mol Cell Cardiol 2003, 35:1113-1119.
11. Mahnood A, Lu D, Lu M, Chopp M: Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003, 53:697-703. The authors show that tail vein injected MSCs significantly improved rat neurological function after controlled traumatic brain injury. Immunohistochemical staining showed donor (human) MSCs in the brain one month after injury.
12. Majumdar MK, Thiede MA, Mosca JD, et al.: Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cellular Physiol 1998, 176:186-192.
13. Chen J, Li Y, Katakowski M, et al.: Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res 2003, 73:778-786.
14. Toma C, Pittenger MF, Cahill KS, et al.: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105:93-98.
15. Tang YL, Zhao Q, Zhang YC, et al.: Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004, 117:3-10.
16. Shake JG, Gruber PJ, Baumgartner WA, et al.: In-vivo mesenchymal stem cell grafting in a swine myocardial infarct model: Molecular and physiologic consequences. Ann Thorac Surg 2002, 73:1919-1926.
17. Itescu S, Schuster MD, Kocher AA: New directions in strategies using cell therapy for heart disease. J Mol Med 2003, 81:288-296.
18. Agbulut O, Menot M-L, Z-L, Marotte F, et al.: Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy. Cardiovasc Res 2003, 58:451-459.
19. Lee J, Z Q-P, Cao B, et al.: Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol 2000, 150:1085-1100.
20. Maitra B, Szekely E, Gjini K, et al.: Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604. This study documents the immunomodulatory effects of MSCs by showing improvement of engraftment kinetics in an allogeneic transplant setting in rodent hosts. The inhibition of T-cell alloreactivity of MMCs may allow transplantation across MHC barriers.
21. Baksh D, Davies JE, Zandstra PW: Adult human bone marrow-derived mesenchymal progenitor cells are capable of adhesion-independent survival and expansion. Exp Hematol 2003, 31:723-732. This study describes a novel method for culturing MSCs in nonadherent culture conditions with the addition of stem cell factor and IL-3 as key additives.
22. Friedenstein AJ, Chailakhjan RK, Lalykina KS: The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinetics 1970, 3:393-403.
23. Haynesworth SE, Baber MA, Caplan AI: Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992, 13:69-80.
24. Lennon DP, Haynesworth SE, Bruder SP, et al.: Development of a serum screen for mesenchymal progenitor cells from bone marrow. In Vitro Cell Dev Biol 1996, 32:602-611.
25. Dennis JE, Haynesworth SE, Young RG, Caplan AI: Osteogenesis in marrow-derived mesenchymal cell porous ceramic composites transplanted subcutaneously: Effect of fibronectin and laminin on cell retention and rate of osteogenic expression. Cell Transplant 1992, 1:23-32.
26. Barry F, Boynton R, Haynesworth S, et al.: The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Comm 1999, 265:134-139.
27. Barry F, Boynton R, Murphy M, et al.: The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Comm 2001, 289:519-524.
28. Simmons PJ, Torok-Storb B: Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62.
29. + fraction of adult human bone marrow contains the osteogenic precursors. Blood 1994, 84:4164-4173.
30. Fickert S, Fiedler J, Brenner RE: Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthr Cart 2003, 11:790-800.
31. Bruder S, Ricalton N, Boynton R, et al.: Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res 1998, 13:655-663.
32. Bruder SB, Horowitz MD, Mosca JD, Haynesworth SE: Monoclonal antibodies reactive with human osteogenic cell surface antigens. Bone 1997, 21:225-235.
33. Wickhan MQ, Drickson FR, Gimble JM, et al.: Multipotent stromal cells derived from the infrapatellar fat fad of the knee. Clin Orthop Rel Res 2003, 412:196-212.
34. Campioni D, Lanza FL, Moretti S, et al.: Functional and immunophenotypic characteristics of isolated CD105+ and fibroblast+ stromal cells from AML: implications for their plasticity along endothelial lineage. Cytother 2003, 5:66-79.
35. Batouli S, Miura M, Brahim J, et al.: Comparison of stem-cell-mediated osteogenesis and dentinogenesis. J Dent Res 2003, 82:976-981.
36. Jiang Y, Jahagirdar B, Reinhard L, et al.: Pluripotent nature of adult marrow derived mesenchymal stem cells. Nature 2002, 418:41-49.
37. Horwitz E, Prockop D, Fitzpatrick L, et al.: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
38. Koc ON, Day J, Nieder M, et al.: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.